Thomas DY - Search Results

1

Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A.

Lopes-Pacheco M, Bacalhau M, Ramalho SS, Silva IAL, Ferreira FC, Carlile GW, Thomas DY, Farinha CM, Hanrahan JW, Amaral MD. Lopes-Pacheco M, et al. Among authors: thomas dy. Cells. 2022 Jan 1;11(1):136. doi: 10.3390/cells11010136. Cells. 2022. PMID: 35011698 Free PMC article.

2

Novel pharmacological strategies to treat cystic fibrosis.

Hanrahan JW, Sampson HM, Thomas DY. Hanrahan JW, et al. Among authors: thomas dy. Trends Pharmacol Sci. 2013 Feb;34(2):119-25. doi: 10.1016/j.tips.2012.11.006. Trends Pharmacol Sci. 2013. PMID: 23380248 Review.

3

Corrector combination therapies for F508del-CFTR.

Hanrahan JW, Matthes E, Carlile G, Thomas DY. Hanrahan JW, et al. Among authors: thomas dy. Curr Opin Pharmacol. 2017 Jun;34:105-111. doi: 10.1016/j.coph.2017.09.016. Epub 2017 Nov 5. Curr Opin Pharmacol. 2017. PMID: 29080476 Review.

4

A novel triple combination of pharmacological chaperones improves F508del-CFTR correction.

Carlile GW, Yang Q, Matthes E, Liao J, Radinovic S, Miyamoto C, Robert R, Hanrahan JW, Thomas DY. Carlile GW, et al. Among authors: thomas dy. Sci Rep. 2018 Jul 30;8(1):11404. doi: 10.1038/s41598-018-29276-y. Sci Rep. 2018. PMID: 30061653 Free PMC article.

5

Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.

Hanrahan JW, Sato Y, Carlile GW, Jansen G, Young JC, Thomas DY. Hanrahan JW, et al. Among authors: thomas dy. Expert Opin Ther Targets. 2019 Aug;23(8):711-724. doi: 10.1080/14728222.2019.1628948. Epub 2019 Jun 9. Expert Opin Ther Targets. 2019. PMID: 31169041 Review.

6

The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR.

Sato Y, Thomas DY, Hanrahan JW. Sato Y, et al. Among authors: thomas dy. J Biol Chem. 2019 Nov 29;294(48):18269-18284. doi: 10.1074/jbc.RA119.010192. Epub 2019 Oct 23. J Biol Chem. 2019. PMID: 31645438 Free PMC article.

7

Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.

Lopes-Pacheco M, Silva IAL, Turner MJ, Carlile GW, Sondo E, Thomas DY, Pedemonte N, Hanrahan JW, Amaral MD. Lopes-Pacheco M, et al. Among authors: thomas dy. Biochem Pharmacol. 2020 Oct;180:114133. doi: 10.1016/j.bcp.2020.114133. Epub 2020 Jul 3. Biochem Pharmacol. 2020. PMID: 32628927

8

The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway.

Carlile GW, Yang Q, Matthes E, Liao J, Birault V, Sneddon HF, Poole DL, Hall CJ, Hanrahan JW, Thomas DY. Carlile GW, et al. Among authors: thomas dy. Sci Rep. 2022 Mar 17;12(1):4595. doi: 10.1038/s41598-022-08661-8. Sci Rep. 2022. PMID: 35302062 Free PMC article.

9

Macrocycle-stabilization of its interaction with 14-3-3 increases plasma membrane localization and activity of CFTR.

Stevers LM, Wolter M, Carlile GW, Macdonald D, Richard L, Gielkens F, Hanrahan JW, Thomas DY, Chakka SK, Peterson ML, Thomas H, Brunsveld L, Ottmann C. Stevers LM, et al. Among authors: thomas dy. Nat Commun. 2022 Jun 23;13(1):3586. doi: 10.1038/s41467-022-31206-6. Nat Commun. 2022. PMID: 35739107 Free PMC article.

10

Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect.

Robert R, Carlile GW, Pavel C, Liu N, Anjos SM, Liao J, Luo Y, Zhang D, Thomas DY, Hanrahan JW. Robert R, et al. Among authors: thomas dy. Mol Pharmacol. 2008 Feb;73(2):478-89. doi: 10.1124/mol.107.040725. Epub 2007 Nov 1. Mol Pharmacol. 2008. PMID: 17975008

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

247 results

Search Page

Filters